Palliative chemotherapy: oxymoron or misunderstanding?
Eric J RoelandT W LeBlancPublished in: BMC palliative care (2016)
Oncologists routinely prescribe chemotherapy for patients with advanced cancer. This practice is sometimes misunderstood by palliative care clinicians, yet data clearly show that chemotherapy can be a powerful palliative intervention when applied appropriately. Clarity regarding the term "palliative chemotherapy" is needed: it is chemotherapy given in the non-curative setting to optimize symptom control, improve quality of life, and sometimes to improve survival. Unfortunately, oncologists lack adequate tools to predict which patients will benefit. In a study recently published in BMC Palliative Care, Creutzfeldt et al. presented an innovative approach to advancing the science in this area: using patient reported outcomes to predict responses to palliative chemotherapy. With further research, investigators may be able to develop predictive models for use at the bedside to inform clinical decision-making about the risks and benefits of treatment. In the meantime, oncologists and palliative care clinicians must work together to reduce the use of "end-of-life chemotherapy"-chemotherapy given close to death, which does not improve longevity or symptom control-while optimizing the use of chemotherapy that has true palliative benefits for patients.
Keyphrases
- palliative care
- advanced cancer
- locally advanced
- patient reported outcomes
- end stage renal disease
- randomized controlled trial
- chronic kidney disease
- newly diagnosed
- squamous cell carcinoma
- healthcare
- primary care
- rectal cancer
- chemotherapy induced
- decision making
- public health
- machine learning
- risk assessment
- combination therapy
- deep learning
- gestational age